LENZ Therapeutics Inc. (LENZ) Income Statement Analysis - Revenue, Earnings & Profitability Metrics - Stocknear
Stocknear Logo Stocknear
/
Popular
  • KO Coca Cola Company Stock
  • TSLA Tesla Inc Stock
  • AMD Advanced Micro Devices Stock
  • SPY SPDR S&P 500 ETF Trust ETF
  • NVDA Nvidia Stock
    • Start Trial

    LENZ Therapeutics Inc.

    NASDAQ: LENZ · Real-Time Price · USD
    41.71
    1.82 (4.56%)
    At close: Sep 10, 2025, 3:59 PM
    41.72
    0.02%
    After-hours: Sep 10, 2025, 07:03 PM EDT

    LENZ Therapeutics Income Statement

    Financials in USD. Fiscal year is January - December.

    undefined peaked at n/a in undefined and hit its lowest at n/a in undefined. Over the past five years, it has declined by undefined%.

    Fiscal Year FY 2024 FY 2023 FY 2022 FY 2021
    Period Ending Dec 31, 2024 Dec 31, 2023 Dec 31, 2022 Dec 31, 2021
    Revenue
    		 n/a n/a 15M n/a
    Cost of Revenue
    		 58K 2.41M 8.35M 734K
    Gross Profit
    		 -58K -2.41M 6.65M -734K
    Operating Income
    		 -58.61M -73.11M -105.64M -60.44M
    Interest Income
    		 8.55M 2.19M n/a n/a
    Pretax Income
    		 -49.77M -124.65M -101.05M -70.76M
    Net Income
    		 -49.77M -124.65M -101.05M -70.76M
    Selling & General & Admin
    		 28.75M 40.97M 32.85M 21.78M
    Research & Development
    		 29.8M 29.73M 64.44M 37.93M
    Other Expenses
    		 n/a n/a 19K n/a
    Operating Expenses
    		 58.55M 70.7M 97.29M 59.71M
    Interest Expense
    		 n/a n/a n/a n/a
    Selling & Marketing Expenses
    		 n/a n/a n/a n/a
    Cost & Expenses
    		 58.61M 73.11M 105.64M 60.44M
    Income Tax Expense
    		 1K -179K 347K 497.44K
    Shares Outstanding (Basic)
    		 21.28M 8.15M 7.84M 8.29M
    Shares Outstanding (Diluted)
    		 21.28M 8.15M 7.84M 8.29M
    EPS (Basic)
    		 -2.34 -15.3 -12.89 -8.54
    EPS (Diluted)
    		 -2.34 -15.3 -12.89 -8.54
    EBITDA
    		 -49.71M -122.24M -97.29M -70.03M
    EBIT
    		 -49.77M -124.65M -10.48M -70.76M
    Depreciation & Amortization
    		 58K 15K 8.35M 734K

    Add to Watchlist